Micafungin
- Generic Name
- Micafungin
- Brand Names
- Mycamine
- Drug Type
- Small Molecule
- Chemical Formula
- C56H71N9O23S
- CAS Number
- 235114-32-6
- Unique Ingredient Identifier
- R10H71BSWG
- Background
Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
- Indication
Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
- Associated Conditions
- Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 172
- Registration Number
- NCT01974375
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
- Conditions
- Graft vs Host DiseaseStem Cell Transplantation
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT01950507
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01888458
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Pharmacokinetics of Micafungin in Patients Intensive Care Unit
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01783379
- Locations
- 🇳🇱
Rijstate Hospital, Arnhem, Netherlands
🇳🇱Gelderse Vallei Hospital, Ede, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Empirical Antifungal Treatment in ICUS
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 260
- Registration Number
- NCT01773876
- Locations
- 🇫🇷
University Hospital of Avicennes, Bobigny, France
🇫🇷Hospital University of Besançon, Besançon, France
🇫🇷Hospital University of Clermont Ferrand, Clermont Ferrand, France
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
- Conditions
- Systemic Fungal Infections
- Interventions
- Drug: Other parenteral antifungal drugs
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 40110
- Registration Number
- NCT01686607
- Locations
- 🇺🇸
Site US4, Baltimore, Maryland, United States
🇺🇸Site US2, Boston, Massachusetts, United States
🇺🇸Site US1, Pittsburgh, Pennsylvania, United States
Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Kevin Watt
- Target Recruit Count
- 18
- Registration Number
- NCT01666769
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT01417169
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Chongno-gu, Korea, Republic of
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
- Conditions
- Febrile NeutropeniaHematological Diseases
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 153
- Registration Number
- NCT01344681
- Locations
- 🇰🇷
Ajou University Medical Center, Suwon, Korea, Republic of
🇰🇷Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT01207128
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸UAMS, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.